| Breakdown | TTM | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.83M | 35.08M | 37.49M | 39.70M | 40.52M | 40.39M |
| Gross Profit | 17.97M | 20.62M | 22.64M | 24.49M | 23.20M | 21.53M |
| EBITDA | 5.80M | 7.26M | 10.55M | 12.82M | 12.14M | 8.83M |
| Net Income | 22.00M | 20.69M | 19.02M | 18.07M | 23.82M | 23.28M |
Balance Sheet | ||||||
| Total Assets | 63.86M | 144.53M | 136.03M | 131.08M | 128.74M | 121.14M |
| Cash, Cash Equivalents and Short-Term Investments | 59.01M | 77.39M | 68.34M | 62.06M | 57.83M | 45.35M |
| Total Debt | 2.61M | 3.58M | 4.78M | 6.13M | 7.37M | 10.79M |
| Total Liabilities | 21.81M | 44.85M | 45.24M | 47.40M | 49.10M | 54.12M |
| Stockholders Equity | 107.76M | 99.68M | 90.79M | 83.67M | 79.64M | 67.01M |
Cash Flow | ||||||
| Free Cash Flow | 19.34M | 20.01M | 17.86M | 18.04M | 24.64M | 16.23M |
| Operating Cash Flow | 19.34M | 20.24M | 17.93M | 18.18M | 24.65M | 16.41M |
| Investing Cash Flow | 13.35M | 21.20M | -10.05M | -26.12M | -3.39M | 7.38M |
| Financing Cash Flow | -13.04M | -11.76M | -11.08M | -14.18M | -10.89M | -9.57M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $40.41B | 36.82 | -74.96% | 1.24% | 9.02% | 3.45% | |
75 Outperform | $7.70B | 16.99 | 28.00% | 1.49% | 5.88% | 12.18% | |
73 Outperform | $340.29M | 15.17 | 20.88% | 3.31% | -3.75% | -4.34% | |
71 Outperform | $76.72B | 37.25 | 62.81% | 0.73% | 8.77% | 13.62% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
67 Neutral | $127.47B | 35.63 | 13.62% | 0.73% | 9.04% | 21.35% | |
64 Neutral | $7.23B | 24.33 | 25.12% | 0.84% | 7.76% | 15.92% |
On December 6, 2025, long-serving Value Line, Inc. director Alfred R. Fiore, who had been on the company’s board since 2010, passed away. On January 16, 2026, the board appointed Dr. Alexander J. Swistel, a retired associate professor at Weill Cornell Medical College with degrees from Harvard University and Brown University School of Medicine, to fill a board seat and serve on the Audit Committee, with standard annual compensation of $40,000; the company emphasized that his selection involved no special arrangements, family relationships, or related-party transactions, underscoring governance independence and continuity in its audit oversight.
The most recent analyst rating on (VALU) stock is a Buy with a $44.00 price target. To see the full list of analyst forecasts on Value Line stock, see the VALU Stock Forecast page.